BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a protein found in human gastric juice. First described by Sikiric et al. in 1993, the compound has been studied primarily for its cytoprotective properties in gastrointestinal tissue, with expanding research into musculoskeletal repair, neuroprotection, and vascular modulation.
The peptide's amino acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) has no known sequence homology with other gut peptides. Unlike many peptides, BPC-157 is stable in human gastric juice — a characteristic that enables oral bioavailability and distinguishes it from most research peptides that require parenteral administration.
As of 2025, a systematic review published in the American Journal of Sports Medicine identified 544 articles on BPC-157 published between 1993 and 2024. Of the 36 that met inclusion criteria for musculoskeletal applications, 35 were preclinical animal studies. Only one was a clinical study (Vasireddi et al., 2025). The gap between preclinical promise and human clinical evidence remains substantial.
BPC-157 appears to influence multiple pathways involved in tissue repair and cytoprotection. The primary mechanisms identified in preclinical research include:
Promotes new blood vessel formation via VEGF upregulation
Enhances GH receptor expression and cell growth pathways
Protects gastric mucosal integrity; stable in gastric juice
Reduces inflammatory cytokines in injury models
Modulates NO pathways involved in vascular function
Supports extracellular matrix formation and fibroblast activity
It is important to note that these mechanisms have been demonstrated primarily in rodent models and cell cultures. The concentrations used in laboratory settings often exceed what might be achieved through typical dosing protocols. Laboratory mechanisms do not guarantee clinical relevance in humans (Vasireddi et al., 2025).
Because BPC-157 has minimal human clinical data, contraindication profiles are derived from its known mechanisms (particularly pro-angiogenic and growth-factor-related activity) and extrapolated from preclinical findings. The following represent areas of concern identified in the literature:
| Condition / Factor | Risk Level | Rationale |
|---|---|---|
| Active cancer or malignancy | HIGH | Pro-angiogenic and growth-factor activity may promote tumor growth |
| Hormone-sensitive cancers (history) | HIGH | Growth hormone receptor upregulation is a theoretical concern |
| Pregnancy / breastfeeding | HIGH | No reproductive toxicology data exists |
| Anaphylaxis history to peptides | HIGH | Immunogenic potential unknown; no allergenicity studies |
| Immunosuppressive therapy | MODERATE | Immune pathway modulation may cause unpredictable interactions |
| Cardiovascular conditions | MODERATE | Vasoactive properties; hemodynamic effects under study |
| Active autoimmune disease | MODERATE | May modulate immune cascades; direction of effect unclear |
| Anticoagulant therapy | MODERATE | Angiogenic activity may interact with bleeding risk |
| Preclinical animal safety | LOW (preclinical) | No adverse effects observed across organ systems in animal models |
| Short-term human tolerance | LOW (limited data) | ~30 total human subjects across 3 small studies; no adverse events reported |
FDA: BPC-157 is classified as a Category 2 bulk drug substance. The FDA has determined it poses significant safety risks due to insufficient human safety data. It cannot be legally compounded by pharmacies for human use under Section 503A of the FD&C Act. It is not approved for any indication.
WADA: Classified under S0: Non-Approved Substances on the Prohibited List since 2022. Prohibited at all times, in and out of competition.
DEA: BPC-157 is not a DEA-scheduled substance. Possession is not illegal (unlike anabolic steroids). However, it cannot be legally prescribed or sold as a drug, food, or dietary supplement.
Market availability: Most BPC-157 sold online carries "research chemical" or "for laboratory research only" labeling. These products are not subject to FDA quality oversight. The Department of Justice has prosecuted compounding pharmacies for distributing BPC-157 (e.g., Tailor Made Compounding LLC, $1.79M forfeiture).
Answer these compound-specific screening questions to evaluate whether BPC-157 research is appropriate given your profile. Enter your email to receive your results.
Enter your email to receive your full BPC-157 readiness report with personalized safety notes: